The U.S. Food and Drug Administration has approved Shield, a blood test designed to help detect colorectal cancer [3].
This development provides a less invasive alternative for patients who avoid traditional screenings. Medical professionals are concerned by a rising trend of colorectal cancer cases in adults under 55 years old [1, 5].
Georgios Karagkounis, a surgeon, said the recommended age to begin screening for individuals with average risk is 45 years [1]. The introduction of Shield and new home-based stool test kits aims to increase compliance rates among this population.
Currently, only about two-thirds of the people who should undergo colorectal screening actually do so [4]. The resistance often stems from the invasive nature of the colonoscopy, or the unpleasantness of traditional fecal tests [1, 5].
While the Shield blood test is now an approved option, it is intended to complement rather than entirely replace the traditional colonoscopy. If a blood or stool test indicates a potential issue, a colonoscopy remains the gold standard for confirmation and polyp removal.
Health providers said the ease of a blood draw may encourage more patients to meet the 45-year-old screening milestone [1]. This shift in accessibility is critical as the medical community observes a steady increase in diagnoses among younger patients [1].
“The recommended age to begin screening for individuals with average risk is 45 years.”
The approval of the Shield test represents a strategic shift toward 'low-friction' diagnostics to combat a growing public health trend: the rise of early-onset colorectal cancer. By lowering the psychological and physical barriers to screening, health officials hope to catch malignancies in earlier, more treatable stages among a demographic that has historically avoided colonoscopies.
